{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+oral+capsules&page=20",
    "query": {
      "intervention": "placebo oral capsules",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 2673,
    "total_pages": 268,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+oral+capsules&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+oral+capsules&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T20:18:56.581Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04625595",
      "title": "Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type1 Diabetes"
      ],
      "interventions": [
        {
          "name": "350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        },
        {
          "name": "700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        },
        {
          "name": "1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        },
        {
          "name": "1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunomolecular Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2020-11-09",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-08-25",
      "last_synced_at": "2026-10-15T20:18:56.581Z",
      "location_count": 3,
      "location_summary": "Chula Vista, California • Aurora, Colorado • Renton, Washington",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Renton",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04625595"
    },
    {
      "nct_id": "NCT05063877",
      "title": "Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "EQU-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Equilibre Biopharmaceuticals B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 43,
      "start_date": "2021-08-31",
      "completion_date": "2023-10-11",
      "has_results": false,
      "last_update_posted_date": "2023-05-15",
      "last_synced_at": "2026-10-15T20:18:56.581Z",
      "location_count": 6,
      "location_summary": "Boise, Idaho • Bethesda, Maryland • Hackensack, New Jersey + 3 more",
      "locations": [
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05063877"
    },
    {
      "nct_id": "NCT00605553",
      "title": "Study to Evaluate SYN115 in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tozadenant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biotie Therapies Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2008-04",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2017-08-08",
      "last_synced_at": "2026-10-15T20:18:56.581Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00605553"
    },
    {
      "nct_id": "NCT04311177",
      "title": "Losartan for Patients With COVID-19 Not Requiring Hospitalization",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Corona Virus Infection",
        "Acute Respiratory Distress Syndrome",
        "SARS-CoV Infection"
      ],
      "interventions": [
        {
          "name": "Losartan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 117,
      "start_date": "2020-04-09",
      "completion_date": "2021-02-01",
      "has_results": true,
      "last_update_posted_date": "2022-05-04",
      "last_synced_at": "2026-10-15T20:18:56.581Z",
      "location_count": 4,
      "location_summary": "Minneapolis, Minnesota • Rochester, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04311177"
    },
    {
      "nct_id": "NCT07288151",
      "title": "MDMA-Assisted Massed Exposure Therapy for PTSD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "3,4-Methylenedioxymethamphetamine (MDMA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Massed Prolonged Exposure (PE)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 200,
      "start_date": "2026-07",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-10-15T20:18:56.581Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07288151"
    },
    {
      "nct_id": "NCT01094262",
      "title": "A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis",
        "Osteoarthritis, Knee",
        "Pain",
        "Arthralgia",
        "Joint Pain"
      ],
      "interventions": [
        {
          "name": "Oxycodone CR (standard pain medication)",
          "type": "DRUG"
        },
        {
          "name": "JNJ-42160443",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 196,
      "start_date": "2010-04-20",
      "completion_date": "2011-07-01",
      "has_results": false,
      "last_update_posted_date": "2020-03-11",
      "last_synced_at": "2026-10-15T20:18:56.581Z",
      "location_count": 36,
      "location_summary": "Tucson, Arizona • Carmichael, California • Pismo Beach, California + 33 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Pismo Beach",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01094262"
    },
    {
      "nct_id": "NCT03291041",
      "title": "A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Jet Lag Disorder"
      ],
      "interventions": [
        {
          "name": "Tasimelteon",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanda Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 25,
      "start_date": "2016-07",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2021-11-03",
      "last_synced_at": "2026-10-15T20:18:56.581Z",
      "location_count": 3,
      "location_summary": "Alameda, California • Santa Monica, California • Chevy Chase, Maryland",
      "locations": [
        {
          "city": "Alameda",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03291041"
    },
    {
      "nct_id": "NCT01874366",
      "title": "Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Overweight",
        "Diabetes Mellitus Type 2 in Obese"
      ],
      "interventions": [
        {
          "name": "P11187",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Piramal Enterprises Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 96,
      "start_date": "2013-06",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2014-08-28",
      "last_synced_at": "2026-10-15T20:18:56.581Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01874366"
    },
    {
      "nct_id": "NCT06382688",
      "title": "IV Administration of ChromaDex's Niagen® as Compared to NAD+",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Aging"
      ],
      "interventions": [
        {
          "name": "NAD+ (nicotinamide adenine dinucleotide) IV",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Niagen® (nicotinamide riboside) IV",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Niagen® (nicotinamide riboside) oral",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Nutraceuticals Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2023-11-13",
      "completion_date": "2024-08-31",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-10-15T20:18:56.581Z",
      "location_count": 1,
      "location_summary": "Franklin, Tennessee",
      "locations": [
        {
          "city": "Franklin",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06382688"
    },
    {
      "nct_id": "NCT00680186",
      "title": "Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran etexilate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2589,
      "start_date": "2008-04",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-05-19",
      "last_synced_at": "2026-10-15T20:18:56.581Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Clearwater, Florida • Normal, Illinois + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00680186"
    }
  ]
}